Last reviewed · How we verify
sham oxygen (room air)
sham oxygen (room air) is a Small molecule drug developed by University of Zurich. It is currently FDA-approved for Placebo control in oxygen therapy trials. Also known as: Nocturnal nasal room air during stay at 2048 m, Nocturnal nasal room air administration.
Sham oxygen (room air) serves as a placebo control in clinical trials, delivering ambient air without supplemental oxygen to assess the true therapeutic effect of oxygen therapy.
Sham oxygen (room air) serves as a placebo control in clinical trials, delivering ambient air without supplemental oxygen to assess the true therapeutic effect of oxygen therapy. Used for Placebo control in oxygen therapy trials.
At a glance
| Generic name | sham oxygen (room air) |
|---|---|
| Also known as | Nocturnal nasal room air during stay at 2048 m, Nocturnal nasal room air administration |
| Sponsor | University of Zurich |
| Modality | Small molecule |
| Therapeutic area | Clinical Research / Methodology |
| Phase | FDA-approved |
Mechanism of action
Sham oxygen is not a therapeutic agent but rather a control intervention used in blinded clinical trials to evaluate the efficacy of actual oxygen therapy. By administering room air (approximately 21% oxygen) in a manner identical to active oxygen treatment, researchers can isolate the placebo effect and determine whether observed clinical benefits are attributable to supplemental oxygen or to other factors such as patient expectation and study design.
Approved indications
- Placebo control in oxygen therapy trials
Common side effects
Key clinical trials
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury (PHASE1, PHASE2)
- Combination Therapy to Improve SCI Recovery. (NA)
- Intermittent Hypoxia in Persons With Multiple Sclerosis (NA)
- Acute Intermittent Hypoxia on Leg Function Following Spinal Cord Injury (NA)
- Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS (NA)
- A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections (PHASE4)
- Acute Intermittent Hypoxia to Improve Airway Protection in Chronic Traumatic Brain Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sham oxygen (room air) CI brief — competitive landscape report
- sham oxygen (room air) updates RSS · CI watch RSS
- University of Zurich portfolio CI
Frequently asked questions about sham oxygen (room air)
What is sham oxygen (room air)?
How does sham oxygen (room air) work?
What is sham oxygen (room air) used for?
Who makes sham oxygen (room air)?
Is sham oxygen (room air) also known as anything else?
What development phase is sham oxygen (room air) in?
Related
- Manufacturer: University of Zurich — full pipeline
- Therapeutic area: All drugs in Clinical Research / Methodology
- Indication: Drugs for Placebo control in oxygen therapy trials
- Also known as: Nocturnal nasal room air during stay at 2048 m, Nocturnal nasal room air administration
- Compare: sham oxygen (room air) vs similar drugs
- Pricing: sham oxygen (room air) cost, discount & access